1. Mevalonate pyrophosphate decarboxylase of rat liver is inhibited by various phenyl and phenolic acids. 2. Some of the phenyl and phenolic acids also inhibited mevalonate phosphate kinase. 3. Compounds with the phenyl-vinyl structure were more effective. 4. Kinetic studies showed that some of the phenolic acids compete with the substrates, mevalonate 5-phosphate and mevalonate 5-pyrophosphate, whereas others inhibit uncompetitively. 5. Dihydroxyphenyl and trihydroxyphenyl compounds and p-chlorophenoxyisobutyrate, a hypocholesterolaemic drug, had no effect on these enzymes. 6. Of the three mevalonate-metabolizing enzymes, mevalonate pyrophosphate decarboxylase has the lowest specific activity and is probably the rate-determining step in this part of the pathway.
Incorporation of mevalonate into cholesterol by homogenates of rat liver and of rat brain is inhibited by phenyl and phenolic acids (Shah et al., 1968 (Shah et al., , 1969 Ranganathan & Ramasarma, 1973 , 1974 . The site of inhibition was found to be between mevalonate and isopentenyl pyrophosphate. In experimental phenylalaninaemia, the concentration of phenylalanine increases in the brain and in the liver, and the incorporation of [2-'4C] (Shah et al., 1968) . These experiments were done with the whole enzyme system shown in Scheme 1 and not with the individual enzymes.
A study was therefore undertaken on the specificity and mechanism of the inhibition by phenyl and phenolic compounds of the three cytosolic mevalonate-metabolizing enzymes that convert mevalonate into isopentenyl pyrophosphate. The results showed that a variety of phenyl and phenolic acids inhibit mevalonate pyrophosphate decarboxylase [ATP-5-diphosphomevalonate carboxylyase (dehydrating); EC 4.1.1.33] and under specified conditions, mevalonate phosphate kinase (ATP-5-phosphomevalonate phosphotransferase; EC 2.7.4.2), but not mevalonate kinase (ATP-mevalonate 5-phosphotransferase; EC 2.7.1.36).
Materials and Methods

Materials
(RS)-[1-14C]Mevalonic acid lactone (6mCi/mmol) was purchased from The Radiochemical Centre, Amersham, Bucks., U.K. Phenyl-lactic acid, phenylpyruvic acid, L-phenylalanine, p-hydroxyphenylacetic acid, p-hydroxybenzoic acid, p-hydroxyphenyl-lactic acid, p-hydroxybenzaldehyde, phydroxyphenylpropionic acid, resorcinol (1,3-di- hydroxybenzene), catechol (1,2-dihydroxybenzene), proteocatechuic acid (3,4-dihydroxybenzoic acid) , L-dopa (3,4-dihydroxyphenylalanine) , p-chlorophenylalanine, DL-3,4-dihydroxyphenyl glycol, and ATP were purchased from Sigma Chemical Co., St. Louis, MO, U.S.A. Cinnamic acid (3-phenyl-2-propenoic acid), p-coumaric acid (4-hydroxycinnamic acid), m-coumaric acid (3-hydroxycinnamic acid), ferulic acid (4-hydroxy-3-methoxycinnamic acid), isoferulic acid (3-hydroxy-4-methoxycinnamic acid), anisic acid (4-methoxybenzoic acid), phloroglucinol (1,3,5-trihydroxybenzene) (Bloch et al., 1959; Porter & Anderson, 1961; Shah et al., 1965 The effects ofaddition ofsome phenolic compounds on liver mevalonate pyrophosphate decarboxylase were tested and compared with those of phenyl acids. The effects of various phenyl and phenolic compounds at a concentration of 2.5 mm are given in Table 2 . The inhibition was progressive with increasing concentrations (1.25-5.0mM) of phenyl and phenolic acids. Of the phenolic compounds tested p-coumaric acid, m-coumaric acid, isoferulic acid, ferulic acid, tyrosine, p-hydroxyphenyl-lactic acid, p-hydroxyphenylacetic acid, p-hydroxybenzoic acid, anisic acid, p-hydroxybenzaldehyde and phydroxyphenylpyruvic acid were all inhibitory. Of these, m-coumaric acid, isoferulic acid, ferulic acid and p-coumaric acid showed higher degrees of inhibition. The phenyl acids, cinnamic acid, phenylalanine, phenyl-lactic acid and phenylpyruvic acid, were also inhibitory.
A kinetic study of inhibition of the phenyl and phenolic compounds is shown in Fig. 2 . Ferulic acid, isoferulic acid, m-coumaric acid, p-coumaric acid, p-hydroxybenzoic acid, p-hydroxyphenyl-lactic acid, cinnamic acid and p-hydroxyphenylpropionic acid compete with the substrate mevalonate 5-pyrophosphate. Uncompetitive inhibition was observed with p-hydroxyphenylacetic acid, p-hydroxybenzaldehyde, anisic acid, L-phenylalanine, tryptophan and p-hydroxyphenylpyruvic acid. All these compounds showed no competition with MgATP (results not shown). Vmax., apparent -Km and K, values are given in Table 3 .
Effects of phenyl and phenolic acids on mevalonate phosphate kinase Mevalonate phosphate kinase was also inhibited by phenyl and phenolic acids after preincubation ( Table 2 ). The degree of inhibition was less compared with that of decarboxylase. There was no significant inhibition byp-hydroxyphenyl-lactic acid,p-hydroxybenzaldehyde and p-hydroxyphenylacetic acid. This is in contrast with the result for decarboxylase, which is inhibited by all of these compounds. The A, p-hydroxybenzaldehyde; *, anisic acid; o, phydroxyphenylpyruvic acid; V, L-phenylalanine; *, no inhibitor. The assay system was as described in Fig. 1 Effects ofp-chlorophenoxyisobutyrate on mevalonate kinase, mevalonate phosphate kinase and mevalonate pyrophosphate decarboxylase p-Chlorophenoxyisobutyrate, a hypocholesterolaemic drug, is known to inhibit the incorporation of mevalonate into cholesterol when added in vitro (Ranganathan & Ramasarma, 1973) , although it had no effect in vivo (Krishnaiah & Ramasarma, 1970) . Walsh et al. (1969) had found that mevalonate kinase from bovine aorta was inhibited by this drug. However, when tested in vitro, it had no effect on mevalonate kinase (results not shown), mevalonate phosphate kinase (Table 2) or mevalonate pyrophosphate decarboxylase (Table 2) up to a concentration of 7.5 mm. The observed inhibition by p-chlorophenoxyisobutyrate on mevalonate incorporation into cholesterol may therefore be at a later step, beyond isopentenyl pyrophosphate. inhibition was progressive with increasing concentration (1.25-7.5 mM) of the inhibitor. The kinetics of inhibition by isoferulic acid, p-coumaric acid and cinnamic acid are shown in Fig. 3 (Table 2) . Except for phloroglucinol, which caused 20% inhibition of the decarboxylase at 2.5mm, the other compounds tested, phloroglucinolcarboxylic acid, syringic acid, resorcinol, catechol, protocatechuic acid, L-dopa, p-chlorophenylalanine and DL-3,4-dihydroxyphenyl glycol, caused no significant change in either of the enzyme activities.
Discussion
Cinnamic acid, ferulic acid, isoferulic acid, pcoumaric acid and m-coumaric acid all showed a high degree of inhibition. All these compounds have a benzene ring and a side chain, -CH=CH-CO2H, in common. Therefore it suggests that, for effective inhibition, a phenyl-vinyl structure is essential. All these compete with the substrates, mevalonate 5-phosphate and mevalonate 5-pyrophosphate. Dihydroxy-and trihydroxy-phenyl compounds have no effect. Side chains with pyruvate, lactate, propionate or acetate groups are all inhibitory, but the degree of inhibition is less than those with -CH=CH-CO2H. Two types of inhibition were seen, competitive and uncompetitive. The compounds that showed competitive inhibition probably have structural similarities to the mevalonate phosphates in solution. Those compounds showing uncompetitive inhibition may affect the enzyme activity by another mechanism.
In phenylketonuria the metabolism of tyrosine is affected in addition to that of phenylalanine (Bickis et al., 1957) . It was found that phenylketonuric subjects excreted large quantities ofp-hydroxyphenyllactic acid and p-hydroxyphenylacetic acid (Boscott & Bickel, 1954) . Phenylalanine and phenylpyruvate at a concentration of 2mM were shown to inhibit the formation of acetoacetate from tyrosine (Bickis et al., 1957) . The concentration of phenylalanine in the plasma of phenylketonuric patients varies from 1 to 4mM. From this it is evident that, in addition to the abnormal metabolism of brain lipids, the phenyl and phenolic acids might also affect liver cholesterol biogenesis by affecting mevalonate phosphate kinase and mevalonate pyrophosphate decarboxylase.
The specific activity of mevalonate pyrophosphate decarboxylase was the lowest ofthe three mevalonatemetabolizing enzymes (Table 1) and may act as the rate-determining enzyme in this part of the pathway. This study also provides us with information on the additional regulatory mechanism. It is well known that the major regulatory enzyme in the biogenesis of cholesterol is 3-hydroxy-3-methylglutaryl-CoA reductase. However, other regulatory sites are also known. Long-term feeding ofcholesterol has been shown to inhibit the incorporation of mevalonate, in addition to acetate, into cholesterol (Bucher et al., 1959; Gould & Swyryd, 1966; Krishnaiah et al., 1967) . Incorporation of mevalonate into non-saponifiable lipids by the liver system was low in suckling rats compared with that in weaned rats (Shah, 1973) , and the decarboxylation of mevalonate was decreased by 50-80% in rats weaned on to cholesterol-supplemented diets (Rarnachandran & Shah, 1976) . It has also been shown that mevalonate decarboxylation (Shama Bhat & Ramasarma, 1977) and mevalonate pyrophosphate decarboxylase exhibit circadian variation. The relative specific activities of 3-hydroxy-3-methylglutaryl-CoA reductase, mevalonate kinase, mevalonate phosphate kinase and mevalonate pyrophosphate decarboxylase at noon and midnight are given in Table 4 . When expressed per g of the liver tissue, the specific activity of 3-hydroxy-3-methylglutaryl-CoA reductase is about 20 times lower than that of decarboxylase. Therefore it is unlikely that the mevalonate-metabolizing enzymes operate at maximum rate, since the substrate is expected to be limiting. In view of the relative excess of decarboxylase it can have a controlling effect on the overall metabolism only if about 70-80% inhibition of its activity is obtained. It may be noted that, at a concentration of 2 mM, some of the phenyl or phenolic compounds can produce such an inhibition. 
1979
The phenolic acids derived from tyrosine are the possible intermediates in the formation ofp-hydroxybenzoic acid, the precursor of the aromatic ring of ubiquinone. The isoprene side chain ofthe ubiquinone molecule is derived from mevalonate. It is noteworthy that the mevalonate pathway is inhibited by p-hydroxybenzoic acid and other phenolic compounds. This offers a model wherein the intermediates of one branch inhibit the other branch in a convergent pathway leading to the synthesis of the end product.
In the present experiments a 4-fold higher concentration of the inhibitor than in previous experiments (Ranganathan & Ramasarma, 1973) 
